Cardiosense has hired Dr. John Martin as EVP and chief medical officer, the Chicago-based cardiac monitoring tech developer said.
Martin is a practicing vascular surgeon and former chief medical officer at Butterfly Network. He said he’ll continue working with the portable ultrasound developer as CMO emeritus.
“I’m the longest running executive at Butterfly,” Martin said in an interview ahead of today’s announcement. “I was there at the beginning, when it was small and we hadn’t even gotten FDA approval. … Now, with the device all over the world and transitioning the way people care for medicine … as someone who’s always embraced new ideas and new technology, the opportunity to take what I’ve learned and try to do it again is what’s exciting about this.”
Martin said he started with Cardiosense around the end of July. (Read more from our interview at Medical Design & Outsourcing.)
Cardiosense recently won FDA 510(k) clearance for its CardioTag device, a wearable that captures high-fidelity electrocardiogram (ECG), photoplethysmogram (PPG), and seismocardiogram (SCG) signals.
Cardiosense also said it hopes to win FDA De Novo classification in the coming year for its AI algorithm that estimates pulmonary capillary wedge pressure (PCWP).
The company says its noninvasive technology could help more patients than hemodynamic sensor implants, offering data to manage heart failure and other volume-sensitive conditions. And in a recent study, the company said its technology can estimate PCWP just as accurately as implantable sensors.
“John’s rare combination of clinical expertise and medtech leadership is precisely what Cardiosense needs during this transformative phase,” Cardiosense co-founder and CEO Amit Gupta said Martin said in a statement shared with MassDevice ahead of the official announcement. “As we complete our validation study for our AI algorithm for cardiac filling pressures and advance towards regulatory submission, John’s leadership will accelerate our mission to expand access to personalized, noninvasive hemodynamic-guided care for the millions living with heart failure and other critical conditions.”
In his own statement, Martin said Cardiosense “is building something truly special at the intersection of AI and medicine.”
“From the operating room to outpatient care, Cardiosense has the potential to transform how we guide therapy, putting actionable, hemodynamic data in the hands of clinicians, and eventually patients, for self-guided care at home,” he continued. “As a practicing physician, I’ve seen firsthand how urgently we need better tools for managing volume in heart failure, and we have a line-of-sight to provide value for other conditions such as renal disease, trauma and more. We’re at a can’t-miss junction to open the aperture beyond heart failure and redefine how we manage volume across conditions and settings — noninvasively, affordably, and at scale.”
Beyond his clinical practice at the University of Maryland Vascular Center at Annapolis, Martin is the founder of cardiovascular nonprofit Heart Health Foundation.
